Skip to main content
Beihai Gofar Chuanshan Biological Co., Ltd. logo

Beihai Gofar Chuanshan Biological Co., Ltd. — Investor Relations & Filings

Ticker · 600538 ISIN · CNE000001DD2 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,020 across all filing types
Latest filing 2026-05-19 Major Shareholding Noti…
Country CN China
Listing Shanghai Stock Exchange 600538

About Beihai Gofar Chuanshan Biological Co., Ltd.

https://www.gofar.com.cn

Beihai Gofar Chuanshan Biological Co., Ltd. specializes in the research, development, and production of marine biological products and pharmaceutical intermediates. The company focuses on the comprehensive utilization of marine resources, particularly the extraction and processing of chitin and chitosan derivatives. Its product portfolio includes health supplements, functional food ingredients, and biochemical raw materials used in various applications such as medicine, agriculture, and environmental protection. By leveraging advanced extraction technologies, the company provides high-purity marine-derived substances to domestic and international markets. Its operations emphasize the transformation of marine biological waste into high-value materials, supporting sustainable industrial practices and the development of marine-based health solutions.

Recent filings

Filing Released Lang Actions
关于控股股东部分股份被司法拍卖过户完成暨权益变动的提示性公告
Major Shareholding Notification Classification · 93% confidence The document is a company announcement disclosing the passive reduction in holdings by the controlling shareholder due to a judicial auction, detailed before-and-after share counts and percentage changes, and noting crossing of the 5% threshold. This matches a Major Shareholding Notification, which reports changes in significant ownership levels.
2026-05-19 Chinese
北京市时代九和律师事务所关于国发股份控股股东、实际控制人变更事项的法律意见书
Regulatory Filings Classification · 85% confidence The document is a legal opinion letter (“法律意见书”) issued by a law firm regarding the change of the controlling shareholder and actual controller of a listed company. It does not contain financial statements, audited results, or serve as an annual or interim report. It is a formal compliance/legal disclosure provided to the exchange. Such standalone legal opinion letters and compliance documents fall under the general “Regulatory Filings” category (RNS).
2026-05-19 Chinese
关于公司原控股股东、实际控制人部分股份司法拍卖过户完成暨公司变更为无控股股东、无实际控制人的提示性公告
Major Shareholding Notification Classification · 87% confidence The document is an official announcement by 北海国发川山生物股份有限公司 regarding the completion of a judicial auction transfer of the original controlling shareholder’s shares and the resulting change to having no controlling shareholder or actual controller. It contains no financial statements or analysis, but details shareholding proportions before and after the judicial transfer (crossing relevant disclosure thresholds). This is a notification of a major shareholding change, so it best fits the “Major Shareholding Notification” category (Code: MRQ).
2026-05-19 Chinese
关于公司控股股东及实际控制人发生变更事项的独立意见
Regulatory Filings Classification · 90% confidence The document is an independent directors’ formal opinion on the change (or absence of change) in the company’s controlling shareholder and actual controller, submitted under listing rules and company law. It is neither a full report (e.g., annual or interim financial report) nor a simple announcement of a meeting result. Instead, it is a compliance/regulatory filing containing an attestation by officers (independent directors) regarding governance matters. Accordingly, it falls under the general Regulatory Filings category (RNS).
2026-05-19 Chinese
简式权益变动报告书
Major Shareholding Notification Classification · 95% confidence The document is titled “简式权益变动报告书” and provides detailed disclosure of shareholding changes by substantial shareholders (crossing a 5% threshold) of the listed company, including pre- and post-change holdings, methods (judicial auction transfer), dates, and legal references. This is a mandatory equity change notification for major shareholders rather than a company report (e.g., annual or interim financial report) or an insider trading statement. It matches the “Major Shareholding Notification” category (MRQ).
2026-05-19 Chinese
董事及高级管理人员薪酬管理办法（2026年修订）
Remuneration Information Classification · 88% confidence The document is a detailed “董事及高级管理人员薪酬管理办法” (Directors and Senior Management Compensation Management Measures), setting out principles, structures, and procedures for board and senior management pay. It is not an AGM notice, financial report, earnings release, or regulatory announcement but rather a comprehensive internal policy on executive and director compensation. This aligns with the Remuneration Information category (DEF 14A).
2026-05-10 Chinese

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.